- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
T-DM1 Achieves Longer Progression-Free Survival vs. Standard Therapy in HER2+ Metastatic Breast Cancer
September 25th 2011, 5:42am
The European Multidisciplinary Cancer Congress
T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.
Panitumumab Extends Progression-Free Survival in HPV-Negative Subset of Advanced Head and Neck Cancer
September 25th 2011, 5:05am
The European Multidisciplinary Cancer Congress
Panitumumab + chemo improves OS and PFS in patients with metastatic carcinoma of the head and neck that were negative for HPV.
Survival Benefit Shown With Investigational Alpha-Emitting Radiopharmaceutical in Men With Hormone Resistant Metastatic Prostate Cancer
September 24th 2011, 4:27pm
The European Multidisciplinary Cancer Congress
Investigational drug that emits alpha radiation shows significant improvement in overall survival.
Novel Infusion Approach Significantly Delays Progression in Uveal Melanoma Patients With Liver Metastases
September 24th 2011, 3:35pm
The European Multidisciplinary Cancer Congress
Patients with liver metastases from uveal melanoma had improved survival after treatment with percutaneous hepatic perfusion (PHP).
Two Predictors of Prostate Cancer Explored in Healthy Men
September 23rd 2011, 9:43am
The European Multidisciplinary Cancer Congress
Two studies enhance understanding of risk factors for prostate cancer.
Image of Stockholm City Hall
September 23rd 2011, 7:24am
The European Multidisciplinary Cancer Congress
The 16th ECCO, 36th ESMO, 30th ESTRO Congresses from the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23-27.
ASCO 2011 Annual Meeting Daily Picture Slideshows
June 8th 2011, 4:43pm
American Society of Clinical Oncology (ASCO) 2011 Annual Meeting Daily Picture Slideshow
Updated Cabozantinib Data Includes 6 Patient Deaths
June 7th 2011, 12:06pm
Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial.
Dr. Vogelzang on Mortalities in the Cabozantinib Trial
June 7th 2011, 11:34am
Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.
Post-Oophorectomy Hormone Replacement Therapy Safe for BRCA1/2 Mutation Carriers
June 7th 2011, 9:42am
Women who present with BRCA1 and BRCA2 mutation face an increased risk of breast and ovarian cancer.
Dr. Infante Talks About BRAF Mutation Testing
June 7th 2011, 9:22am
Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing
PTEN Expression Does Not Diminish Trastuzumab Effectiveness
June 7th 2011, 8:08am
Phosphatase and tensin homolog (PTEN)-positive breast cancer can be treated with trastuzumab (Herceptin) as effectively as PTEN-negative breast cancer
ASCO 2011 Annual Meeting Picture Slideshow Day Four
June 7th 2011, 7:31am
American Society of Clinical Oncology 2011 Annual Meeting Picture Slideshow Day Four
Axitinib Outperforms Sorafenib in Renal Cell Carcinoma Trial
June 7th 2011, 6:04am
Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib
Deciphering the Challenge of the Genomic Era in Breast Cancer
June 6th 2011, 10:09am
Luminal A genetic signature in node-negative, estrogen receptor- (ER-) positive breast cancer predicts a very high disease-free survival rate
Rethinking Initial Management of Patients With Brain Metastasis and HER2 Breast Cancer
June 6th 2011, 9:47am
Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer
Two Studies Herald New Era in Melanoma Therapy
June 6th 2011, 7:07am
New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted
Three-Year Imatinib Regimen Delivers Optimal GIST Treatment
June 6th 2011, 6:47am
3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival
Pemetrexed Maintenance Improves Progression-Free Survival in Patients With NSCLC
June 6th 2011, 6:37am
Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer
Dr. Wolchok Describes the Immunotherapy Ipilimumab
June 6th 2011, 6:26am
Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab